Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver

Table 1 Patient characteristics, maximum toxicity, maximum response, adverse events, and arterial hypovascularisation under therapy.

Patient number	Age (yr)	Gender	Maximum number of gemcitabine cycles	Maximum number of chemo- occlusion cycles	Maximum response	Neutro- penia acc. To WHO	Thrombo- penia acc. To WHO	Anemia acc. To WHO	Choles- tasis acc. To WHO	Nausea acc. To WHO	Flush symptoms acc. To WHO	Tumor- related disease	Clinical therapy related benefit	Progressive arterial hypovascu- larization
1	60	M	5	2	SD	2	2	2	2	2	1	yes	-	-
2	71	F	4	1	SD	2	2	1	2	2	1	yes	-	-
3	67	F	11	3	PR	1	1	1	2	0	1	-	-	yes
4	47	F	7	3 (+11)	PR	1	0	1	1	2	2	yes	-	yes
5	63	F	9	2 (+11)	PR	0	0	1	2	1	1	yes	yes	yes
6	76	F	6	2 (+11)	SD	0	0	0	0	1	1	yes	yes	yes
7	53	F	9	2	SD	0	1	1	2	2	2	yes	yes	-
8	56	M	4	1	SD	0	0	2	2	1	2	yes	-	-

¹Single chemoperfusion without DSM because of early vascular stasis due to progressive arterial hypovascularization.